Updated Jul 16, 2026 · Last SEC filing 2026-07-01
Lexeo Therapeutics, Inc. (LXEO) has filed 13 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-01. 4 Form 8-K material event filings were reported by LXEO in the last 90 days. 7 Form 144 notices of proposed sale were filed for LXEO stock. InsiderAlpha tracks every LXEO SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
|---|---|
| SEC CIK | 0001907108 |
| Form 4 filings (90d) | 13 |
|---|---|
| Form 8-K filings (90d) | 4 |
| Form 144 notices (90d) | 7 |
| Latest Form 4 filing | 2026-07-01 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Tamayo Louis Edward | Chief Financial Officer | S — Open-market sale | 4.6K | $4.49 | $21K | SEC | |
| Townsend Richard Nolan | Chief Executive Officer | S — Open-market sale | 25.9K | $4.48 | $116K | SEC | |
| Bhalla Narinder Pal | Chief Medical Officer | S — Open-market sale | 22.3K | $4.42 | $99K | SEC | |
| Otero Jose Manuel | Chief Operating Officer | S — Open-market sale | 4.7K | $4.48 | $21K | SEC | |
| Bhalla Narinder Pal | Chief Medical Officer | A — Grant or award | 55.0K | $0.00 | — | SEC | |
| Tamayo Louis Edward | Chief Financial Officer | A — Grant or award | 12.0K | $0.00 | — | SEC | |
| Townsend Richard Nolan | Chief Executive Officer | A — Grant or award | 67.0K | $0.00 | — | SEC | |
| Otero Jose Manuel | Chief Operating Officer | A — Grant or award | 12.1K | $0.00 | — | SEC | |
| Townsend Richard Nolan | Chief Executive Officer | S — Open-market sale | 3.3K | $5.06 | $17K | SEC | |
| Otero Jose Manuel | Chief Operating Officer | S — Open-market sale | 1.3K | $5.07 | $7K | SEC | |
| Townsend Richard Nolan | Chief Executive Officer | S — Open-market sale [10b5-1] | 55.0K | $5.69 | $313K | SEC | |
| Townsend Richard Nolan | Chief Executive Officer | A — Grant or award | 2.6K | $2.64 | $7K | SEC | |
| Otero Jose Manuel | Chief Operating Officer | A — Grant or award | 5.9K | $2.64 | $16K | SEC | |
| Otero Jose Manuel | Chief Operating Officer | S — Open-market sale | 3.0K | $6.40 | $19K | SEC | |
| Townsend Richard Nolan | Chief Executive Officer | S — Open-market sale | 10.2K | $6.38 | $65K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Lexeo Therapeutics, Inc. (LXEO). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Otero Jose Manuel | 3 | $28K |
| Townsend Richard Nolan | 3 | $133K |
| Bhalla Narinder Pal | 2 | $99K |
| Tamayo Louis Edward | 2 | $21K |
| Agger Mette Kirstine | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in LXEO insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live LXEO dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.